jump to content jump to footer
Interview with Prof. Timm Denecke about the RACOON-MARDER project and AI-powered early detection of liver cancer using MRI
An in-depth interview with Prof. Timm Denecke about the RACOON-MARDER project

Rethinking Early Detection: How RACOON-MARDER Aims to Spot Liver Cancer Sooner

Hepatocellular carcinoma (HCC) is often diagnosed too late, limiting treatment options and survival. The RACOON-MARDER project aims to change that. By combining MRI imaging, clinical data, and AI-based risk stratification, researchers hope to identify high-risk patients earlier and enable personalized, intensified surveillance beyond what traditional ultrasound can offer.

In this interview, Prof. Dr. Timm Denecke (University Hospital Leipzig) explains how AI can make the invisible visible - and why the RACOON infrastructure is key to advancing liver cancer research.

Read more here.

Interview mintLesion Clinical Research Multi-center Research HCC Personalized Therapy RACOON AI Structured Reporting

Related Resources

mint Lesion usage during a clinical trial read, featuring the TGRM export tool.
Bridging the Gap Between RECIST and Survival: Why the FDA’s Analysis of the g Value is a Game-Changer

For decades, oncology trials have relied on RECIST 1.1 to evaluate drug efficacy. However, these categorical "snapshot" evaluations do not always…

Participants at the RECIST and Beyond workshop in Cologne during hands-on training with mint Lesion for structured tumor response assessment.
The two-day “RECIST and Beyond” workshop at radCIO Cologne offered intensive hands-on training on RECIST, iRECIST, mRECIST and LI-RADS, with real-case reporting performed directly in mint Lesion.
Successful “RECIST and Beyond” Workshop in Cologne: Advancing Precision in Oncologic Imaging

How can complex tumor findings be assessed accurately, reproducibly, and in line with clinical guidelines?

Screenshot of the mint Lesion interface showing RANO 2.0 configuration, tumor burden calculations, and structured neuro-oncology assessment tools.
mint Lesion fully supports RANO 2.0 implementation with configurable parameters, automated tumor burden calculations, and structured workflows for neuro-oncology clinical trials.
Implementing RANO 2.0 for Neuro-Oncology Clinical Trials in mint Lesion

Tumor response assessment in neuro-oncology clinical trials requires careful attention to measurement protocols and confirmation scan requirements. To…